Table 1 TCGA queue CLDN7 correlation with clinical pathological characteristics [n (%)]
From: Expression and clinical significance of CLDN7 and its immune-related cells in breast cancer
Clinical Features | Total | CLDN7 high expression | CLDN7 low expression | χ2 | P |
|---|---|---|---|---|---|
(N = 908) | (N = 366) | (N = 542) | |||
Age/year | Â | Â | Â | 3.059 | 0.08 |
<60 | 499(54.96) | 214(58.47) | 285(52.58) | Â | Â |
≥ 60 | 409(45.04) | 152(41.53) | 257(47.42) |  |  |
Gender | Â | Â | Â | Â | Â |
Female | 897(98.79) | 363(99.18) | 534(98.52) | 0.826 | 0.363 |
Male | 11(1.21) | 3(0.82) | 8(1.48) | Â | Â |
AJCC Stage | Â | Â | Â | 3.287 | 0.349 |
I | 160(17.62) | 57(15.57) | 103(19.00) | Â | Â |
II | 532(58.59) | 214(58.47) | 318(58.67) | Â | Â |
III | 199(21.92) | 86(23.50) | 113(20.85) | Â | Â |
IV | 17(1.87) | 9(2.46) | 8(1.48) | Â | Â |
T | Â | Â | Â | 5.657 | 0.13 |
T1 | 236(25.99) | 145(39.62) | 91(16.48) | Â | Â |
T2 | 538(59.25) | 326(89.07) | 212(39.11) | Â | Â |
T3 | 102(11.23) | 58(15.85) | 44(8.12) | Â | Â |
T4 | 32(3.52) | 13(3.55) | 19(3.51) | Â | Â |
N | Â | Â | Â | 2.073 | 0.557 |
N0 | 450(49.56) | 171(46.72) | 279(51.48) | Â | Â |
N1 | 301(33.15) | 127(34.70) | 174(32.10) | Â | Â |
N2 | 103(11.34) | 44(12.02) | 59(10.89) | Â | Â |
N3 | 53(5.84) | 24(6.56) | 30(5.54) | Â | Â |
M | Â | Â | Â | 1.149 | 0.284 |
M0 | 891(98.13) | 357(97.54) | 534(98.52) | Â | Â |
M1 | 17(1.87) | 9(2.46) | 8(1.48) | Â | Â |
ESR1 | Â | Â | Â | 8.578 | 0.003 |
+ | 340(37.44) | 158(43.17) | 182(33.58) | Â | Â |
- | 568(62.56) | 208(56.83) | 360(66.42) | Â | Â |
ERBB2 | Â | Â | Â | Â | Â |
+ | 14(15.75) | 76(20.77) | 67(12.36) | 11.627 | 0.001 |
- | 765(84.25) | 290(79.23) | 475(87.64) | Â | Â |
PGR | Â | Â | Â | 0.045 | 0.833 |
+ | 257(28.30) | 105(28.69) | 152(28.04) | Â | Â |
- | 651(71.70) | 261(71.31) | 390(71.96) | Â | Â |